Ambrx Biopharma Inc. to Present at Upcoming Investor Conferences

SAN DIEGO–(BUSINESS WIRE)–Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced that Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx, will present at two upcoming investor conferences in May. Bank of America 2022 Healthcare Conference. Dr. Tian will participate in an analyst led fireside chat on Wednesday, May 11 at 12:00 PM
Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks